Payment overview · 2025
General Payments
$6,511.66
315 reported records · 38 companies
Healthcare provider profile · identity verified
James L Strong, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · BIRMINGHAM, AL · NPI 1619970290
Verified facts
What the public records show
CMS Open Payments records show James L Strong, MD received $6,511.66 in general payments during 2025 across 315 reported records.
ABBVIE INC. accounted for 12.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 52 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Briviact, Fycompa, Hizentra, Nurtec Odt, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Ubrelvy by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Fycompa by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Hizentra as an associated drug or biological on 13634 records involving 4691 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Hizentra by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xcopri by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trintellix by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $817.05 | 12.6% | 51 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $494.16 | 7.6% | 28 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $459.69 | 7.1% | 16 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $450.11 | 6.9% | 18 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$296.57 | 4.5% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $293.43 | 4.5% | 15 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $247.91 | 3.8% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $240.37 | 3.7% | 14 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $233.73 | 3.6% | 13 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $220.22 | 3.4% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $209.98 | 3.2% | 11 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $186.54 | 2.9% | 8 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $178.74 | 2.7% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $178.64 | 2.7% | 11 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $170.96 | 2.6% | 8 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $162.33 | 2.5% | 12 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $161.81 | 2.5% | 7 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $148.29 | 2.3% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $142.40 | 2.2% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $136.24 | 2.1% | 7 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $135.15 | 2.1% | 6 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $134.55 | 2.1% | 6 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $126.72 | 1.9% | 7 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $116.33 | 1.8% | 4 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $83.88 | 1.3% | 5 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $76.19 | 1.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $72.02 | 1.1% | 4 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $67.00 | 1.0% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $50.90 | 0.8% | 2 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $38.71 | 0.6% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $27.77 | 0.4% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.79 | 0.4% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $24.43 | 0.4% | 1 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $22.35 | 0.3% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.90 | 0.3% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.55 | 0.3% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.00 | 0.3% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $15.25 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $6,511.66 | 315 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $459.69 | 16 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $451.65 | 25 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $451.65 | 25 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $400.47 | 20 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $354.38 | 26 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $345.70 | 14 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $326.51 | 23 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $293.43 | 15 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $229.73 | 8 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $195.86 | 12 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $186.54 | 8 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $184.53 | 10 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $178.74 | 7 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $170.96 | 8 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $162.33 | 12 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $161.86 | 10 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $149.54 | 6 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $148.29 | 5 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $142.40 | 5 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $135.15 | 6 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $130.46 | 4 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $120.41 | 5 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $116.33 | 4 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $111.10 | 6 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $108.25 | 7 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $108.25 | 7 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $105.11 | 4 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $100.30 | 3 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $100.30 | 3 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $83.88 | 5 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $72.02 | 4 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $67.00 | 3 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $64.42 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka Pharmaceutical Development & Commercialization, Inc. | $55.56 | 4 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $51.18 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $50.90 | 2 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $44.51 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $42.51 | 3 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $39.85 | 3 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $38.74 | 4 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $38.71 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $37.86 | 2 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $27.77 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $15.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 30 | exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Hizentra hizentra |
2025 | Hizentra | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 98 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 135 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
30 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
98 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
135 | 33 |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Hizentra open payments reported associated product |
CMS Open Payments — General Payments 13634 supporting records · 4691 recipient NPIs · example record 1232339012 |
Hizentra · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 334 | 74 |
| Gabapentin | Gabapentin | 323 | 70 |
| Clonazepam | Clonazepam | 251 | 34 |
| Donepezil Hcl | Donepezil Hcl | 238 | 54 |
| Levetiracetam | Levetiracetam | 178 | 37 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 177 | 41 |
| Pregabalin | Pregabalin | 164 | 28 |
| Lacosamide | Lacosamide | 137 | 17 |
| Ubrelvy | Ubrogepant | 135 | 33 |
| Qulipta | Atogepant | 98 | 21 |
| Baclofen | Baclofen | 84 | 19 |
| Topiramate | Topiramate | 77 | 20 |
| Lamotrigine | Lamotrigine | 73 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 17 |
| Prednisone | Prednisone | 64 | 21 |
| Emgality Pen | Galcanezumab-Gnlm | 54 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 12 |
| Alprazolam | Alprazolam | 46 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 46 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 46 | 12 |
| Mirtazapine | Mirtazapine | 45 | 12 |
| Butalbital-Acetaminophen | Butalbital/Acetaminophen | 44 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 44 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 43 | suppressed |
| Fycompa | Perampanel | 43 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 43 | suppressed |
| Primidone | Primidone | 41 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 33 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | 11 |
| Temazepam | Temazepam | 33 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Botox | Onabotulinumtoxina | 30 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Phenobarbital | Phenobarbital | 29 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 28 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Zonisamide | Zonisamide | 27 | suppressed |
| Lamotrigine Er | Lamotrigine | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 25 | suppressed |
| Levetiracetam Er | Levetiracetam | 25 | suppressed |
| Carbamazepine Er | Carbamazepine | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 24 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 19 | suppressed |
| Neupro | Rotigotine | 19 | suppressed |
| Carbidopa | Carbidopa | 18 | suppressed |
| Galantamine Er | Galantamine Hbr | 18 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 16 | suppressed |
| Briviact | Brivaracetam | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 12 | suppressed |
| Banzel | Rufinamide | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Zolmitriptan | Zolmitriptan | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Protriptyline Hcl | Protriptyline Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Xcopri | Cenobamate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,511.66 · 315 records | ABBVIE INC. | ACTHAR, AMPYRA, AUSTEDO XR, AVONEX, Auvelity, BOTOX, BRIUMVI, Bafiertam, Briviact, CREXONT, Dysport, EMGALITY, EPIDIOLEX, FYCOMPA, Fintepla, HYQVIA, Hizentra, INBRIJA, INGREZZA, JOURNAVX, KESIMPTA, KISUNLA, LEQEMBI, Motpoly XR, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus, Ocrevus Zunovo, PANZYGA, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Rystiggo, Symbravo, TANLOR, TREMFYA, TRUDHESA, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, WAINUA, Xeomin, ZAVZPRET, ZEPOSIA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error